Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combining a budgetary-impact analysis and a cost-effectiveness analysis using decision-analytic modelling techniques.

Mark J C Nuijten1, Frans Rutten

  • 1MEDTAP International, Amsterdam, The Netherlands.

Pharmacoeconomics
|September 19, 2002
PubMed
Summary

A new modeling technique allows for simultaneous assessment of a new drug's budget impact and cost-effectiveness. This approach, demonstrated in Parkinson's disease, offers a unified method for evaluating new medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incorporating angina into the H<sub>2</sub>FPEF score improves diagnostic performance for HFpEF in women.

Open heart·2026
Same author

The plasma proteome is linked to echocardiographic parameters and stages of diastolic dysfunction, across the ejection fraction spectrum.

International journal of cardiology·2025
Same author

Sex differences in the prescription of antihypertensive medications in primary care patients: an observational study.

BJGP open·2025
Same author

Longitudinal cardiac imaging for assessment of myocardial injury in non-hospitalised community-dwelling individuals after COVID-19 infection: the Rotterdam Study.

Heart (British Cardiac Society)·2025
Same author

Huisarts en wetenschap·2023
Same author

Electrocardiographic Features of Left Ventricular Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Systematic Review.

Frontiers in cardiovascular medicine·2022

Area of Science:

  • Health Economics
  • Pharmacoeconomics
  • Clinical Research Methodology

Background:

  • Drug reimbursement decisions often rely on budgetary impact, with growing demand for cost-effectiveness data.
  • Assessing new pharmaceuticals requires robust methods for both economic and clinical evaluations.

Purpose of the Study:

  • To introduce a unified modeling technique for assessing both the budgetary impact and cost-effectiveness of new drugs.
  • To illustrate this methodology using a hypothetical Parkinson's disease drug model from a societal perspective.

Main Methods:

  • Developed a two-step modeling approach: a simple Markov model for epidemiological validation, followed by an extended semi-Markov model.
  • Incorporated disease progression, drug utilization, and healthcare resource patterns for Parkinson's disease treatment.

Related Experiment Videos

Main Results:

  • Significant differences in epidemiological data between simple and complex models underscore the need for advanced models with higher external validity.
  • The complex model effectively assessed potential drug candidates and their cost-effectiveness compared to standard care.

Conclusions:

  • A single, comprehensive model can adequately assess both the budgetary impact and cost-effectiveness of new pharmaceutical interventions.